ACAdeline Crinier

Adeline Crinier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adeline Crinier has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Eric Vivier

    Innate Pharma, Marseille, France

    3 shared publications
  • Emilie Narni-Mancinelli

    Aix Marseille Université, INSERM, CNRS, Centre d’Immunologie de Marseille-Luminy

    2 shared publications
  • Eric Vivier

    Aix Marseille Université, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Immunologie de Marseille-Luminy (CIML), Marseille, France

    2 shared publications
  • Frédéric Vély

    Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France; Immunology, Marseille Immunopole, Hôpital de la Timone, Assistance Publique des Hôpitaux de Marseille, France

    2 shared publications
  • Mathilde Girard-Madoux

    Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France

    2 shared publications
  • Mikaël Ebbo

    Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France; Immunology, Marseille Immunopole, Hôpital de la Timone, Assistance Publique des Hôpitaux de Marseille, France; Internal Medicine, Hôpital de la Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France

    2 shared publications

Latest Publications

  • Targeting natural killer cells in solid tumors

    by Guillaume Habif, Adeline Crinier, Pascale André, Eric Vivier, Emilie Narni-Mancinelli

    Natural killer (NK) cells are innate lymphoid cells endowed with cytolytic activity and a capacity to secrete cytokines and chemokines. Several lines of evidence suggest that NK cells play an important role in anti-tumor immunity. Some therapies against hematological malignacies make use of the immune properties of NK cells, such as their ability to kill residual leukemic blasts efficiently after conditioning during haploidentical hematopoietic stem cell transplantation. However, knowledge on NK cell infiltration and the status of NK cell responsiveness in solid tumors is limited so far. The pro-angiogenic role of the recently described NK cell-like type 1 innate lymphoid cells (ILC1s) and their phenotypic resemblance to NK cells are confounding factors that add a level of complexity, at least in mice. Here, we review the current knowledge on the presence and function of NK cells in solid tumors as well as the immunotherapeutic approaches designed to harness NK cell functions in these conditions, including those that aim to reinforce conventional anti-tumor therapies to increase the chances of successful treatment.


  • Open Access

    Helper-like innate lymphoid cells and cancer immunotherapy

    by Adeline Crinier, Eric Vivier, Mathieu Bléry


  • Open Access

    High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice

    by Adeline Crinier, Pierre Milpied, Bertrand Escalière, Christelle Piperoglou, Justine Galluso, Anaïs Balsamo, Lionel Spinelli, Inaki Cervera-Marzal, Mikaël Ebbo, Mathilde Girard-Madoux, et al.


  • Innate lymphoid cells: major players in inflammatory diseases

    by Mikaël Ebbo, Adeline Crinier, Frédéric Vély, Eric Vivier

    Recent years have seen a marked increase in our understanding of innate lymphoid cells (ILCs). ILCs can be classified into different groups based on their similarity to T cell subsets in terms of their expression of key transcription factors and cytokine production. Various immunological functions of ILCs have been described, and increasing numbers of studies have implicated these cells in inflammatory disorders. Here, we detail the roles of ILCs in inflammatory diseases; we cover type 2 inflammatory diseases (such as asthma, chronic rhinosinusitis and atopic dermatitis), as well as inflammatory bowel diseases, psoriasis and other systemic or organ-specific inflammatory and autoimmune diseases. Future directions in the field are discussed, together with potential avenues of treatment.


  • Les cellules lymphoïdes innées

    by Adeline Crinier, Charlotte Viant, Mathilde Girard-Madoux, Éric Vivier

    Innate Lymphoid Cells (ILC) are tissue-resident effector lymphocytes that differ from the B and T lymphocytes subsets since they lack specific antigen receptors derived from gene rearrangements. They can be divided into two groups, cytotoxic ILC (NK cells) which are dependent on the transcription factors Eomes and T-bet and produce IFN-γ, and helper-like ILC (ILC1, ILC2, ILC3) which are dependent on T-bet, GATA-3 or RORγT and produce IFN-γ, IL-5/IL-13 or IL-17/IL-22 respectively. Although they were described recently, ILC are the subject of a large number of studies that characterize their role as one of the first effectors of the innate immune response as well as in the development of a wide number of inflammatory disorders.